Literature DB >> 1345961

Allogeneic bone-marrow transplantation without protective isolation in adults with malignant disease.

J A Russell1, M C Poon, A R Jones, R C Woodman, B A Ruether.   

Abstract

Bone-marrow transplant (BMT) patients are severely immunocompromised immediately after the procedure and they are commonly nursed in strict protective isolation to reduce the risk of both infection and graft-versus-host disease (GvHD). We have studied a consecutive series of patients to see whether protective isolation is of benefit as prophylaxis against infectious complications of BMT. 50 consecutive patients who had malignant disease and received their first BMT from siblings or unrelated donors were nursed in standard single rooms with visitors instructed to wash their hands. A subset of 20 patients living locally spent a median of 25 days in hospital after BMT; they also spent some time at home on a median of 8 days before engraftment and 3 patients went home on more than 90% of their hospital days. 16 patients (32%) had positive bacterial cultures and/or focal infection. Gram-positive bacteraemia was found in 12 subjects (24%) but there were no gram-negative or deep fungal infections. Grade II or III acute GvHD developed in 17 patients (34%). There were no deaths from infection or acute GvHD. Transplant-related mortality was 6% in the first 100 days and 18% overall with a median follow-up of 22 months. Our mortality data compare favourably with those from institutions with strict isolation procedures. We conclude that BMT may be safely completed in some institutions without either protective isolation or the need to confine patients continuously in hospital.

Entities:  

Mesh:

Year:  1992        PMID: 1345961     DOI: 10.1016/0140-6736(92)90153-t

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  5 in total

1.  Long-term outcome in patients treated at home during the pancytopenic phase after allogeneic haematopoietic stem cell transplantation.

Authors:  Olle Ringdén; Behnam Sadeghi; Gianluca Moretti; Sigrun Finnbogadottir; Brita Eriksson; Jonas Mattsson; Britt-Marie Svahn; Mats Remberger
Journal:  Int J Hematol       Date:  2017-11-15       Impact factor: 2.490

2.  General health, symptom occurrence, and self-efficacy in adult survivors after allogeneic hematopoietic stem cell transplantation: a cross-sectional comparison between hospital care and home care.

Authors:  Karin Bergkvist; Jeanette Winterling; Eva Johansson; Unn-Britt Johansson; Britt-Marie Svahn; Mats Remberger; Jonas Mattsson; Joacim Larsen
Journal:  Support Care Cancer       Date:  2014-10-17       Impact factor: 3.603

3.  Variation in supportive care practices in hematopoietic cell transplantation.

Authors:  Stephanie J Lee; Claudia C Astigarraga; Mary Eapen; Andrew S Artz; Stella M Davies; Richard Champlin; Madan Jagasia; Nancy A Kernan; Fausto R Loberiza; Margaret Bevans; Robert J Soiffer; Steven Joffe
Journal:  Biol Blood Marrow Transplant       Date:  2008-11       Impact factor: 5.742

4.  Home-Based Hematopoietic Cell Transplantation in the United States.

Authors:  Anthony D Sung; Vinay K Giri; Helen Tang; Krista Rowe Nichols; Meagan V Lew; Lauren Bohannon; Yi Ren; Sin-Ho Jung; Tara Dalton; Amy Bush; Jolien Van Opstal; Alexandra Artica; Julia Messina; Rebecca Shelby; Jennifer Frith; Martha Lassiter; Jill Burleson; Kari Leonard; Ashley S Potter; Taewoong Choi; Cristina J Gasparetto; Mitchell E Horwitz; Gwynn D Long; Richard D Lopez; Stefanie Sarantopoulos; Nelson J Chao
Journal:  Transplant Cell Ther       Date:  2022-01-20

5.  Hospital and community acquired infection and the built environment--design and testing of infection control rooms.

Authors:  J T Walker; P Hoffman; A M Bennett; M C Vos; M Thomas; N Tomlinson
Journal:  J Hosp Infect       Date:  2007-06       Impact factor: 3.926

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.